All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

When you look at the chart here, you can see that we have ... we also are now taking Fabhalta into myasthenia gravis to give another option for those patients, and as I mentioned, immune reset ...

Excitingly, in myasthenia [gravis], we have entered the advanced therapy era with the approval of the complement inhibitors starting in 2017, and now, more recently, the FcRn [neonatal Fc receptor ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations and those who did not experience exacerbations. Higher health care ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...

and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. “We are excited to announce this new strategic partnership for a ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

TG has finally revealed the next indication for Briumvi – myasthenia gravis. This looks like an obvious next step for Briumvi since B cell depletion is a validated mechanism for this condition ...

Management's intention to shift the focus to pipeline development was seen as a positive step, although the timing ... obesity, and myasthenia gravis (MG). Regeneron's management has been working ...